Replies to post #40 on Matinas Biopharma Holdings Inc (MTNB)

[The Lawman]

If MTNB strings together 10 consecutive days of a $2 share price, the company can uplist to NYSE Market. This should be a major catalyst, along with the results of the two clinical trials expected to be announced in the next few months. Big things appear to be on the horizon for this exciting company.